智通财经APP讯，中华燃气(08246)发布公告，根据2025年10月20日订立的贷款资本化协议并于2025年12 月8日的股东特别大会上获得独立股东特别授权配发及发行1.4亿股资本化股份。 ...

中发展控股(00475)发布公告，于2025年11月28日，本公司(作为发行人)、胡杨俊先生(作为债权人)与瀚 海资本(作为认购人)订立贷款资本化协议，各订约方有条件同意，瀚海资本将认购而本公司将按资本化 价格每股资本化股份0.4港元配发及发行8750万股资本化股份。瀚海资本应付的所有资本化股份的总认 购价将须于贷款资本化完成后，透过资本化及抵销部分贷款的方式结付。 考虑到本集团目前的财务状况，本集团在不抽紧现有财务资源的情况下并无能力偿还欠付胡先生的款 项。贷款资本化使本集团能够在不动用现有财务资源的情况下清偿部分现有负债，并可避免现金流出。 8750万股资本化股份相当于本公告日期已发行股份总数约21.23%;及假设已发行股份总数自本公告日期 起直至贷款资本化协议完成并无变动，经配发及发行资本化股份扩大的已发行股份总数约17.51%。 ...

考虑到本集团目前的财务状况，本集团在不抽紧现有财务资源的情况下并无能力偿还欠付胡先生的款 项。贷款资本化使本集团能够在不动用现有财务资源的情况下清偿部分现有负债，并可避免现金流出。 8750万股资本化股份相当于本公告日期已发行股份总数约21.23%;及假设已发行股份总数自本公告日期 起直至贷款资本化协议完成并无变动，经配发及发行资本化股份扩大的已发行股份总数约17.51%。 智通财经APP讯，中发展控股(00475)发布公告，于2025年11月28日，本公司(作为发行人)、胡杨俊先生 (作为债权人)与瀚海资本(作为认购人)订立贷款资本化协议，各订约方有条件同意，瀚海资本将认购而 本公司将按资本化价格每股资本化股份0.4港元配发及发行8750万股资本化股份。瀚海资本应付的所有 资本化股份的总认购价将须于贷款资本化完成后，透过资本化及抵销部分贷款的方式结付。 ...

Core Viewpoint - Jixing New Energy announced a loan capitalization agreement to settle shareholder loans and issue capitalized shares to Mr. Liu, indicating a strategic move to manage debt and equity structure [1] Group 1: Loan Capitalization Agreement - The company, Jixing New Energy, entered into a loan capitalization agreement on November 3, 2023, with a conditional agreement to settle shareholder loans amounting to CAD 3,838,150 (approximately HKD 21,337,280.41) in full [1] - The agreement includes the issuance of 210,000,000 capitalized shares at an issue price of HKD 0.30 per share to Mr. Liu, aimed at settling a portion of the debt amounting to CAD 7,494,290 (approximately HKD 41,662,719.59) [1] Group 2: Impact on Share Capital - The capitalized shares represent approximately 34.65% of the company's issued share capital as of the announcement date [1] - After the issuance of the capitalized shares, they will account for about 25.73% of the enlarged issued share capital of the company [1] - The company plans to apply for approval from the Stock Exchange Listing Committee for the listing and trading of the capitalized shares [1]

Group 1 - The company, Jixing New Energy (03395), has entered into a loan capitalization agreement to settle shareholder loans of CAD 3.8382 million and issue 210 million capitalization shares at HKD 0.30 each to settle debts amounting to CAD 7.4943 million (approximately HKD 41,662,719.59) [1] - The capitalization shares will represent approximately 25.73% of the company's enlarged issued share capital, assuming no changes in the issued share capital between the announcement date and the completion date [1] - The issue price of HKD 0.30 per capitalization share reflects a discount of about 1.64% compared to the closing price of HKD 0.305 on the Hong Kong Stock Exchange on the date of the loan capitalization agreement [1] Group 2 - The loan settlement plan allows the company to repay existing debts without utilizing existing internal financial resources, thus avoiding cash outflow [2] - Upon completion of the agreement, the company's debt ratio will decrease, improving its financial condition [2] - The ongoing property exploration and development will require substantial additional capital investment, and failure to secure further financing or raise funds through asset sales could delay or suspend the development of promising properties [2]

Group 1 - The company, Jixing New Energy (03395), has entered into a loan capitalization agreement to settle shareholder loans of CAD 3.8382 million and issue 210 million capitalization shares at HKD 0.30 each to settle debts amounting to CAD 7.4943 million (approximately HKD 41,662,719.59) [1] - The capitalization shares will represent approximately 25.73% of the company's enlarged issued share capital, assuming no changes in the issued share capital between the announcement date and the completion date [1] - The issue price of HKD 0.30 per capitalization share reflects a discount of about 1.64% compared to the closing price of HKD 0.305 on the date of the loan capitalization agreement [1] Group 2 - The loan settlement plan allows the company to clear existing liabilities without utilizing internal financial resources, thus avoiding cash outflow [2] - Upon completion, the company's debt ratio will decrease, improving its financial condition [2] - The ongoing property exploration and development require substantial additional capital investment, and failure to secure further financing or raise funds through asset sales could delay or suspend the development of promising properties [2]

Core Viewpoint - China National Pharmaceutical Group Technology Co., Ltd. (国药科技股份) reported a significant improvement in its financial performance for the year ending June 30, 2025, with a revenue increase of approximately 48% year-on-year, reaching about HKD 61.3 million, and a substantial reduction in net loss by about 95% to approximately HKD 0.9 million [1] Financial Performance - Revenue for the year was approximately HKD 61.3 million, representing a year-on-year increase of about 48% [1] - The loss attributable to owners was approximately HKD 0.9 million, a significant decrease of about 95% compared to the previous year [1] - Earnings per share reflected a loss of HKD 0.0019 [1] Factors Contributing to Performance - The revenue growth was primarily driven by increased demand in the health products market and improved operational efficiency in supply chain services, highlighting the effectiveness of the company's strategic focus on these core business areas [1] - The board noted several key factors contributing to the improved financial performance, including: - A year-on-year gross profit increase of approximately HKD 9.2 million or 184% due to business improvements [1] - Enhanced cost control over administrative and operational expenses [1] - Capitalized loan income of approximately HKD 3.9 million for the year [1] - Reduced financing costs due to loan capitalization during the year [1]

Core Viewpoint - The company, Tian Cai Holdings, is engaging in significant capital transactions involving its indirect non-wholly owned subsidiary, JSC, to enhance its operational capacity and financial stability in response to market conditions, particularly the U.S. tariff situation [1][3]. Group 1: Capital Injection and Share Issuance - On July 7, 2025, SL Vietnam, an indirect non-wholly owned subsidiary of the company, entered into a capital injection agreement with JSC, agreeing to subscribe for new shares representing 26.89% of JSC's total issued share capital as of the announcement date, with a total subscription price of $1,000,000 for general working capital [1]. - Following the completion of the capital injection, SL Imaging, a wholly-owned subsidiary, will also enter into a loan capitalization agreement with JSC, agreeing to subscribe for capitalized shares representing 54.38% of JSC's total issued share capital as of the announcement date, with a total issuance price of $11,000,000 to capitalize outstanding loan principal [1][3]. Group 2: Ownership Structure Post Transactions - After the completion of the capital injection and loan capitalization, SL Vietnam will enter into a purchase agreement to acquire shares from the seller, which will result in the company holding 99.45% of JSC's total issued share capital, with 69.45% held through SL Vietnam and 30.00% through SL Imaging [2]. - As of the announcement date, the group holds 73.70% of JSC's issued share capital, with the seller and independent third parties holding 25.31% and 0.99%, respectively [2]. Group 3: Financial Impact and Strategic Goals - The capital injection and loan capitalization are expected to improve JSC's capital structure and debt ratio, thereby enhancing its ability to expand production facilities and capacity in Vietnam amid U.S. tariff challenges [3].